Pfizer and BioNTech hit back against CureVac suit over Covid-19 vaccine patents
After its Covid-19 vaccine candidate petered out, CureVac earlier this month filed suit against BioNTech in German court, stating that CureVac should be compensated for the alleged infringement of a range of patents.
However, BioNTech made clear that it is willing to go to the mat against CureVac, and it brought on its partner Pfizer in a Massachusetts court filing to counter what they see as groundless claims.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.